Dr. Mehmet Oz to Lead CMS with Focus on Expanding Medicare Advantage
Dr. Mehmet Oz confirmed as CMS Administrator with mandate to protect and grow Medicare Advantage, improving care and reducing costs for seniors.
Medicare Advantage Drives Growth in Home Health Care Use, Study Finds
Study reveals shifting patterns in home health care use among Medicare Advantage enrollees, highlighting implications for care quality, equity, and policy in U.S. Medicare programs.
U.S. Health Policy Update: Autism Research, Drug Pricing, HHS Cuts, and Preventive Care Coverage
Insights on recent shifts in U.S. health policy: autism research, drug pricing reforms, HHS operational cuts, abortion access, and legal challenges to insurance preventive care coverage.
Rising Social Security Service Delays Stress Houston Offices Amid Staffing Cuts
Social Security in Houston faces increasing delays due to staffing cuts and higher call volumes, impacting benefit approvals and service access. Learn how these challenges affect Texas beneficiaries and federal service modernization efforts.
HaysMed CEO Represents Rural Healthcare at HHS Policy Roundtable
HaysMed CEO Edward Herrman joined a key HHS healthcare policy roundtable discussing rural healthcare challenges, Medicare Advantage concerns, regulatory burdens, and AI opportunities. Insights to inform federal support and reform.
Impact of Proposed Medicaid and Medicare Cuts on Massachusetts Care Providers
U.S. Rep. Richard Neal discusses the potential impact of federal budget cuts to Medicaid and Medicare on Massachusetts long-term care providers and residents.
Medicare Drug Coverage and Costs for Jardiance in Heart Failure and Diabetes Care
Explore how Medicare Part D and C plans cover Jardiance for heart failure and type 2 diabetes, including costs, formularies, and pricing reforms under the Inflation Reduction Act.
Medicare Drug Cost Sharing Shifts Drive Higher Patient Expenses
Medicare beneficiaries face higher costs as Part D plans shift from fixed co-pays to coinsurance for expensive Tier 3 drugs, raising out-of-pocket expenses significantly.
Caremark Faces Whistleblower Lawsuit Over Medicare Part D Overbilling Claims
Caremark is accused of overbilling Medicare Part D by $240-$330 million in a whistleblower lawsuit, raising significant regulatory and compliance concerns for PBMs.
Medicare Genetic Testing Fraud Case Settled for $6M Over False Claims
Genexe and Immerge settle $6M case resolving false Medicare claims for unnecessary genetic tests involving kickbacks. Settlement addresses healthcare fraud and whistleblower suits under the False Claims Act.